Over the past few decades, engineers have developed various devices that can create holograms, three-dimensional (3D) or ...

A new approach for identifying signs of hidden awareness in people who cannot speak or move after severe brain injury has ...

Men diagnosed with metastatic prostate cancer that lacks the PTEN protein now have a targeted drug option for the first time.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today provides shareholders a ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...

The wAIHA market landscape is undergoing a significant evolution after years of dependence on broad immunosuppressive ...

Advances in soft materials are reshaping the design of next-generation devices, particularly where flexibility, adaptability, ...

Multi-Waveform Wireless Prototype Will Deliver Operational Aerial Surveillance and Response ISAC is a mission-first ...

A deep reinforcement learning framework optimizes silicon-based photonic crystal fiber modulators, achieving ultra-low ...

The development of the 6G standard is entering a more concrete phase. At the June 2026 3GPP RAN Plenary in Singapore, the industry advanced several key areas under study and finalized the timeline for ...

Capivasertib plus abiraterone/prednisone improved radiographic PFS in PTEN-deficient mAPMN/S prostate cancer (CAPItello-281) and launched with a VENTANA PTEN ...